Importantly, co-inhibition of the MAPK and PI3K/AKT/mTOR pathways using a MEK inhibitor and everolimus, an mTOR inhibitor, showed a reduction in tumor burden in two different MPNST-forming GEMMs [54]. The gene discussed is MTOR; the disease is neoplasm.